Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07427797 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. In this study, all participants will receive a single injection of either IPN10200 or placebo (the study drug). There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period (Day 1) where all the eligible participants will receive a single injection of IPN10200 or placebo. * A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit. Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.
Conditions Studied
Interventions
- BIOLOGICAL IPN10200
- BIOLOGICAL Placebo
Study Locations (20)
California
- Ablon Skin Institute and Research Center — Manhattan Beach
- Keith A. Marcus, MD Inc — Redondo Beach
- West Dermatology — San Diego
- Ava T. Shamban, M.D., Inc. — Santa Monica
- Art of Skin MD — Solana Beach
- Pacific Clinical Innovations Inc. — Vista
Arizona
- Advanced Research Associates — Glendale
- Avacare — Scottsdale
- Investigate MD, LLC — Scottsdale
Texas
- Westlake Dermatology & Cosmetic Surgery - Westlake — Austin
- Dermatology and Laser Surgery Center — Houston
- Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research — Pflugerville
British Columbia
- Carruthers and Humphrey Cosmetic Medicine — Vancouver
- Pacific Dermaesthetics Inc. — Vancouver
Alabama
- Skin Wellness Dermatology - Homewood — Birmingham
Florida
- Skin Research Institute — Coral Gables
Maryland
- ICON Dermatology and Aesthetics — Bethesda
South Carolina
- Clinical Research Center of the Carolinas — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07427797
The ClinicalTrials.gov registry entry for NCT07427797 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 205 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Moderate to Severe Glabellar Lines appearing as the primary indexed condition, and to 2 interventions — of which IPN10200 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07427797 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Arizona, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07427797 about?
NCT07427797 is a clinical study titled "A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows". The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable...
What is the current status of trial NCT07427797?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-02-27. Estimated completion is 2027-07-15.
What conditions does trial NCT07427797 study?
This clinical trial studies the following conditions: Moderate to Severe Glabellar Lines. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07427797?
The interventions under investigation include: IPN10200 (BIOLOGICAL), Placebo (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07427797?
This trial is sponsored by Ipsen, which has 205 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07427797 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.